NurExone Biologic Inc., a pharmaceutical company, engages in the development of novel, biologic, and minimal-invasive treatment for the spinal cord and traumatic brain injury. It develops a biological extracellular vesicles-based technology drug platform to treat damage in the central nerve system. The company was founded in 2020 and is based in Toronto, Canada.